Stockscreener 앱 받기
25.18
5.93%
1.41
시간 외 거래:
25.18
전일 마감가:
$23.77
열려 있는:
$23.84
하루 거래량:
1.21M
Relative Volume:
1.69
시가총액:
$1.17B
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
17.37
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
+14.09%
1개월 성능:
+8.63%
6개월 성능:
-3.52%
1년 성능:
+12.61%
1일 변동 폭
$23.50
$25.23
1주일 범위
$21.70
$25.23
52주 변동 폭
$11.16
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.18 | 1.01B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Doma Perpetual's 5.7% Stake in Pacira Biosciences: A Catalyst for Governance Change or Strategic Alignment? - AInvest
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $25.75 - Defense World
Will Pacira BioSciences Inc. stock recover after recent dropSwing Trade Entry and Exit Point Analysis - Newser
Is Pacira BioSciences Inc. building a consolidation baseAI Trading Forecast Based on Big Data - Newser
How Pacira BioSciences Inc. stock performs during market volatilityGrowth Watchlist for Long Term Positioning - Newser
Signal strength of Pacira BioSciences Inc. stock in tech scannersSecure Buy Strategy Based on Risk Parameters - Newser
Order flow analysis tools used on Pacira BioSciences Inc.Free Trade Insight With Community Collaboration - Newser
Real time alert setup for Pacira BioSciences Inc. performanceReal-Time Investment Picks with Accuracy - Newser
Doma Perpetual Discloses 5.7% Stake in Pacira Biosciences - MarketScreener
Can machine learning forecast Pacira BioSciences Inc. recoveryRisk Balanced Picks for Safer Trading - Newser
Trend analysis for Pacira BioSciences Inc. this weekLow Volatility Stock Analysis With Confidence - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIFree Chart Breakout Buy Signal Detection - Newser
Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Lifted by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Earnings visualization tools for Pacira BioSciences Inc.Free Daily Growth Stock Pick Reports - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Pacira BioSciences Inc. rally from current levelsStrong Buy Opportunity with Volume Support - Newser
Pacira Biosciences Q2 Earnings Call Highlights Growth and Strategy Amid Challenges - AInvest
Pacira BioSciences Reports Q2 2025 Results: EPS of -$0.11 Misses Estimates, Revenue at $181.1 Million Below Expectations - AInvest
Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M - AInvest
New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Momentum Entry Alerts with Risk Control - Newser
Pacira Biosciences shares rise 2.09% intraday after Q2 revenue beat expectations. - AInvest
Pacira Biosciences Q2 Non-GAAP Earnings Fall, Revenue Rises; Updates 2025 Sales Forecast - MarketScreener
Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance - AInvest
Pacira BioSciences (PCRX) Bolsters Growth with Strategic Moves - GuruFocus
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... - Yahoo Finance
Pacira BioSciences' Q2 2025: Contradictions Surface on EXPAREL Market Access, Sales, and Margins - AInvest
Pacira BioSciences Q2 2025 Earnings Call Transcript: Key Takeaways - AInvest
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences Q2 2025 Earnings Call Transcript - MarketBeat
Pacira BioSciences Reports Q2 2025 Financial Results - TipRanks
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences: A Strategic Turnaround in the Opioid-Alternative Sector - AInvest
Pacira Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacira BioSciences' Q2 revenue misses estimates - MarketScreener
Pacira BioSciences reports Q2 2025 rev. $181.1mln, net loss $4.8mln. - AInvest
Pacira BioSciences Reports Second Quarter 2025 Financial Results - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Exit strategy if you’re trapped in Pacira BioSciences Inc.Risk Balanced Picks for Safer Trading - Newser
What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings - Yahoo Finance
What makes Pacira BioSciences Inc. stock price move sharplyCapitalize on market momentum for maximum profit - Jammu Links News
What are analysts’ price targets for Pacira BioSciences Inc. in the next 12 monthsRapid market gains - Jammu Links News
What is the dividend policy of Pacira BioSciences Inc. stockMarket-beating returns - Jammu Links News
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Investors to Inquire about Securities Investigation - ACCESS Newswire
What is the risk reward ratio of investing in Pacira BioSciences Inc. stockStay informed with expert market forecasts - Jammu Links News
What analysts say about Pacira BioSciences Inc. stockBuild wealth faster with expert stock selection - Jammu Links News
What are the latest earnings results for Pacira BioSciences Inc.Massive profits - Jammu Links News
How does Pacira BioSciences Inc. compare to its industry peersMarket-crushing profits - Jammu Links News
Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):